Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Long-Term Investments (2025 - 2026)

Centessa Pharmaceuticals has reported Long-Term Investments over the past 1 years, most recently at $282.5 million for Q4 2025.

  • Quarterly Long-Term Investments changed N/A to $282.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $282.5 million through Dec 2025, changed N/A year-over-year, with the annual reading at $282.5 million for FY2025, N/A changed from the prior year.
  • Long-Term Investments was $282.5 million for Q4 2025 at Centessa Pharmaceuticals, up from $102.8 million in the prior quarter.
  • Over five years, Long-Term Investments peaked at $282.5 million in Q4 2025 and troughed at $102.8 million in Q3 2025.